Radnostix, Inc.
Moat Score — Radnostix, Inc.
Total Moat Score
11 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | An FDA-approved generic sodium iodide I-131 product and NRC radioactive-materials licenses represent real, slow-to-replicate regulatory assets, though the company holds no blockbuster patents and competes against larger, better-capitalized specialty suppliers. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | Radnostix is a sub-scale domestic producer competing against larger players like Nordion in cobalt-60 and Jubilant DraxImage in I-131; it markets supply security rather than cost leadership. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Customer concentration (top three customers at 31% of 2025 revenue) and declining FY2025 revenue and gross margin suggest limited ability to push through price increases against established competitors. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Radioisotope manufacturing and calibration-standard sales exhibit no network effect; a customer's value from RadQual calibration standards does not increase as more customers adopt them. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 2 / 5 | Imaging equipment makers and hospitals that qualify RadQual calibration standards into their regulatory and quality processes face some switching friction, but theranostics and cobalt-60 customers can generally re-source from Nordion, Jubilant DraxImage, or government producers. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The regulatory burden of NRC licensing, FDA registration, and DOT transport authorization keeps the number of qualified radioisotope suppliers small, giving incumbents like Radnostix a durable, if modest, scale-driven barrier against new entrants. |